Explore the latest advancements and treatments for mucocutaneous lesions, focusing on drug approvals, resistant herpes strains, and care in immunocompromised patients.
FDA Approves Hovilpri for Herpes Lesions Resistant to Antiviral Treatment in Immunocompromised Adults